177 related articles for article (PubMed ID: 36721000)
1. Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction.
Tong J; Tan X; Hao S; Ermine K; Lu X; Liu Z; Jha A; Yu J; Zhang L
Oncogene; 2023 Mar; 42(12):869-880. PubMed ID: 36721000
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade.
Tong J; Tan X; Song X; Gao M; Risnik D; Hao S; Ermine K; Wang P; Li H; Huang Y; Yu J; Zhang L
Cancer Res; 2022 Apr; 82(7):1340-1352. PubMed ID: 35149588
[TBL] [Abstract][Full Text] [Related]
3. BET Inhibitors Potentiate Chemotherapy and Killing of
Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.
He K; Zheng X; Li M; Zhang L; Yu J
Oncogene; 2016 Jan; 35(2):148-57. PubMed ID: 25867072
[TBL] [Abstract][Full Text] [Related]
5. STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Huang DY; Chao Y; Tai MH; Yu YH; Lin WW
J Biomed Sci; 2012 Mar; 19(1):35. PubMed ID: 22462553
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of autophagy by 3-MA potentiates purvalanol-induced apoptosis in Bax deficient HCT 116 colon cancer cells.
Coker-Gurkan A; Arisan ED; Obakan P; Guvenir E; Unsal NP
Exp Cell Res; 2014 Oct; 328(1):87-98. PubMed ID: 25088259
[TBL] [Abstract][Full Text] [Related]
7. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.
Stolfi C; Caruso R; Franzè E; Rizzo A; Rotondi A; Monteleone I; Fantini MC; Pallone F; Monteleone G
Mol Cancer Ther; 2011 Oct; 10(10):1969-81. PubMed ID: 21817114
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB.
Oliver Metzig M; Fuchs D; Tagscherer KE; Gröne HJ; Schirmacher P; Roth W
Oncogene; 2016 Jun; 35(26):3399-409. PubMed ID: 26522725
[TBL] [Abstract][Full Text] [Related]
9. Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.
Yue D; Sun X
Cancer Biol Ther; 2019; 20(3):284-294. PubMed ID: 30359552
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.
Wang W; Kim SH; El-Deiry WS
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11003-8. PubMed ID: 16835297
[TBL] [Abstract][Full Text] [Related]
11. Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells.
Liu J; Edagawa M; Goshima H; Inoue M; Yagita H; Liu Z; Kitajima S
Biochem Biophys Res Commun; 2014 Mar; 445(2):320-6. PubMed ID: 24530917
[TBL] [Abstract][Full Text] [Related]
12. Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation.
Xiao Q; Qian Z; Zhang W; Liu J; Hu E; Zhang J; Li M; Wang J; Kong F; Li Y; Wang R; Tan X; He D; Xiao X
Oncotarget; 2016 Feb; 7(8):9513-24. PubMed ID: 26843620
[TBL] [Abstract][Full Text] [Related]
13. The ellagic acid-derived gut microbiota metabolite, urolithin A, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells.
González-Sarrías A; Tomé-Carneiro J; Bellesia A; Tomás-Barberán FA; Espín JC
Food Funct; 2015 May; 6(5):1460-9. PubMed ID: 25857357
[TBL] [Abstract][Full Text] [Related]
14. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
15. Promising Anticancer Activity of Multitarget Cyclin Dependent Kinase Inhibitors against Human Colorectal Carcinoma Cells.
Manohar SM; Joshi KS
Curr Mol Pharmacol; 2022; 15(7):1024-1033. PubMed ID: 35068399
[TBL] [Abstract][Full Text] [Related]
16. CDK inhibitors in cancer therapy, an overview of recent development.
Zhang M; Zhang L; Hei R; Li X; Cai H; Wu X; Zheng Q; Cai C
Am J Cancer Res; 2021; 11(5):1913-1935. PubMed ID: 34094661
[TBL] [Abstract][Full Text] [Related]
17. Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73.
Lu C; Wang W; El-Deiry WS
Cancer Biol Ther; 2008 Dec; 7(12):2039-46. PubMed ID: 19106635
[TBL] [Abstract][Full Text] [Related]
18. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
Nandi S; Dey R; Dey S; Samadder A; Saxena AK
Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
[TBL] [Abstract][Full Text] [Related]
19. PNUTS knockdown potentiates the apoptotic effect of Roscovitine in breast and colon cancer cells.
De Leon G; Cavino M; D'Angelo M; Krucher NA
Int J Oncol; 2010 May; 36(5):1269-75. PubMed ID: 20372802
[TBL] [Abstract][Full Text] [Related]
20. An Overview of CDK Enzyme Inhibitors in Cancer Therapy.
Mounika P; Gurupadayya B; Kumar HY; Namitha B
Curr Cancer Drug Targets; 2023; 23(8):603-619. PubMed ID: 36959160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
